Prairie Capital V recapitalizes National Enzyme Company

Prairie Capital V recapitalizes National Enzyme Company

November 10, 2015

Chicago, IL - November 2015 National Enzyme Company was founded in 1932 and is based in Forsythe, Missouri. The company is the leading manufacturer of specialty enzymes for the digestive health market.

National Enzyme Company serves as a contract manufacturer of vitamins and supplements and offers its customers end-to-end product management, including ingredients, formulation development, creative packaging and label design, production and packaging, and laboratory testing. In addition to digestive enzymes, the company produces probiotics, vitamins, minerals, botanicals, extracts and other products. National Enzyme Company serves customers both in the US and internationally.

Prairie Capital partnered with Skyline Global Partners and Management to acquire National Enzyme Company from its shareholders.

For more information on National Enzyme Company, please contact:
Darren Snyder at [email protected]Sean McNally at [email protected]

 

Prairie Capital, founded in 1997, is a Chicago-based private equity firm focused on facilitating ownership transitions for lower middle market companies. Prairie targets companies with annual recurring revenue and cash flow of at least $20 million and $4 million, respectively. Prairie is typically the first institutional investor in these entrepreneurial companies, with an aim toward growing and professionalizing the businesses. Prairie's strengths include: exceptional responsiveness, a partner oriented, entrepreneurial approach and great flexibility in structuring investments.

Since its inception, Prairie has worked with talented entrepreneurs and experienced management teams across more than 80 platform investments, investing in the aggregate approximately $700 million. Prairie is currently investing from its fifth fund, the $300 million, Prairie Capital V, L.P.